Skip to main content
SpringerLink
Log in

Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Cabergoline (CAB) treatment is an effective, safe and well tolerated approach for hyperprolactinemia. We investigated the efficacy of 24-month treatment with CAB in 37 patients with previously untreated PRL-secreting pituitary adenoma and evaluated the hormonal and neuroradiological changes after the discontinuation of long-term therapy. Eleven patients with macroprolactinoma (1M/10F) and 26 with microprolactinoma (4M/22F) started treatment taking 0.25 mg CAB twice a week for 4 weeks. The dose was increased stepwise in 0.5 mg increments until reaching lowest maximally effective and tolerated dose. CAB was withdrawn before the end of the study in 6 women who became pregnant and in one patient who showed a slight increase of the macroadenoma at MRI. During treatment, PRL levels decreased significantly in macro (11.1±1.1 vs 407.8±98.3 μg/l, p<0.001) and microprolactinomas (11.1±1.6 vs 193.8±23.4 μg/l, p<0.05) and normalized in all macro and in 23/26 microprolactinomas. In 3 cases PRL levels decreased but did not normalize because the appearance of side effects, such as nausea or hypotension, prevented the increase of the dose of CAB. The effective dose of drug correlated significantly with basal serum PRL levels (p<0.05) and with the pituitary tumor size (p<0.05). A significant decrease of the mean adenoma size was evident for macro (6.9±1.8 vs 16.0±1.8 mm, p<0.001) and microprolactinomas (3.0±0.5 vs 6.5±0.4 mm, p<0.001) at MRI. The tumor disappeared in 4 macroadenomas and in 11 microadenomas after 12 months of treatment. CAB withdrawal was followed by serum PRL increase in 13 cases after 3 months, in 6 after 6 months, in 2 after 9 months, and in one patient at the 12th month. Five patients showed normo-prolactinemia with negative MRI after one year. Regular menses were restored in 7/10 macro-prolactinomas and in all oligo-amenorrhoic patients with microadenoma; serum testosterone levels normalized in 2/3 hypogonadic men. Five out of 6 women become pregnant and had uneventful pregnancies which resulted in deliveries of normal babies. In conclusion, this study confirms the effectiveness and safety of CAB for patients with PRL-secreting pituitary adenoma and suggests that it can be considered a first choice treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 1992, 13: 220.

    Article  CAS  PubMed  Google Scholar 

  2. Crosignani P.G., Ferrari C., Liuzzi A., Benco R., Mattei A., Rampini P., Dellabonzana D., Scarduelli C., Spelta B. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline and lisuride. Fertil. Steril. 1982, 37: 61.

    CAS  PubMed  Google Scholar 

  3. Franks S., Horrocks P.M., Lynch S.S., Butt W.R., London D.R. Effectiveness of pergolide mesylate in long-term treatment of hyperprolactinaemia. Br. Med. J. 1983, 286: 1177,.

    Article  CAS  Google Scholar 

  4. Ferrari C., Barbieri C., Caldara R., Mucci M., Codecasa F., Paracchi A., Romano C., Boghen M., Dubini A. Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 1986, 63: 941.

    Article  CAS  PubMed  Google Scholar 

  5. Dallabonzana D., Liuzzi A., Opizzi G., Cozzi R., Verde G., Chiodini P.G., Rainer E., Dorow R., Horowski R. Chronic treatment of pathological hyperprolactine-mia and acromegaly with the new ergot derivative terguride. J. Clin. Endocrinol. Metab. 1986, 63: 1002.

    Article  CAS  PubMed  Google Scholar 

  6. Rasmussen C., Bergh T., Wide L., Brownell J. CV 205–502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin. Endocrinol.(Oxf.) 1987, 26: 321.

    Article  CAS  Google Scholar 

  7. Benker G., Gieshoff B., Freundlieb O., Windeck R., Schute H.M., Lancranjan I., Reinwein D. Parenteral bromocriptine in the treatment of hor-monally active pituitary tumours. Clin. Endocrinol. (Oxf.) 1986, 24: 505.

    Article  CAS  Google Scholar 

  8. Kletzky O.A., Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil. Steril. 1989, 51: 269.

    CAS  PubMed  Google Scholar 

  9. Ferrari C., Mattei A., Melis G.B., Paracchi A., Muratori M., Faglia G., Sghedoni D., Crosignani P.G. Cabergoline: long-acting oral treatment of hyper-prolactinemic disorders. J. Clin. Endocrinol. Metab. 1989, 68: 1201.

    Article  CAS  PubMed  Google Scholar 

  10. Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hypeprolactinemic patients. J. Clin. Endocrinol. Metab. 1989, 69: 725.

    Article  CAS  PubMed  Google Scholar 

  11. Ferrari C., Paracchi A., Mattei A., de Vincentiis S., D’Alberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperpro-lactinemic disorders. Acta Endocrinol. (Copenh.) 1992, 126: 489.

    CAS  Google Scholar 

  12. Pellegrini I., Rasolonjanahary R., Gunz G., Bertrand P., Delivet S., Jedynak C.P., Kordon C., Peillon F., Jaquet P., Enjalbert A. Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 1989, 69: 500.

    Article  CAS  PubMed  Google Scholar 

  13. Colao A., Di Sarno A., Sarnacchiaro F., Ferone D., Di Renzo G., Merola B., Annunziato L., Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 1997, 82: 876.

    Article  CAS  PubMed  Google Scholar 

  14. Delgrange E., Maiter D., Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur. J. Endocrinol. 1996, 134: 456.

    Article  Google Scholar 

  15. Biller B.M.K., Molitch M.E., Vance M.L., Cannistraro K.B., Davis K.R., Simons J.A., Schoenfelder J.R., Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 1996, 81: 2338.

    CAS  PubMed  Google Scholar 

  16. Ferrari C.I., Abs R., Bevan J.S., Brabant G., Ciccarelli E., Motta T., Mucci M., Muratori M., Musatti L., Verbessem G., Scanlon M.F. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin. Endocrinol. (Oxf.), 1997, 46: 409.

    Article  CAS  Google Scholar 

  17. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 1994, 331: 904.

    Article  CAS  PubMed  Google Scholar 

  18. Webster J., Piscitelli G., Polli A., D’Alberon A., Falsetti L., Ferrari C., Fioretti P., Giordano G., L’Hermite M., Ciccarelli E., Crosignani P.G, De Cecco L., Fadini R., Faglia G., Flamigni C., Tamburrano G., Ismail I., Scanlon M.F. (European Multicentre Cabergoline Study Group). The efficacy and tolerability of long-term cabergo-line therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin. Endocrinol. (Oxf.), 1993, 39: 323.

    Article  CAS  Google Scholar 

  19. Mattei A.M., Ferrari C., Baroldi P., Cavioni V., Paracchi A., Galparoli C., Romano C., Spellecchia D., Gerevini G., Crosignani P.G. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hypeprolactinemic patients. J. Clin. Endocrinol. Metab. 1988, 66: 193.

    Article  CAS  PubMed  Google Scholar 

  20. Molitch M.E. Pregnancy and the hyperprolactinemic woman. N. Engl. J. Med. 1985, 312: 1364.

    Article  CAS  PubMed  Google Scholar 

  21. Robert E., Musatti L., Piscitelli G., Ferrari C.I. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 1996, 10: 333.

    Article  CAS  PubMed  Google Scholar 

  22. Ciccarelli E., Grottoli S., Razzore P., Gaia D., Bertagna A., Cirillo S., Cammarota T., Camanni M., Camanni F. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J. Endocrinol. Invest. 1997, 20: 547.

    CAS  PubMed  Google Scholar 

  23. Colao A., Di Sarno A., Landi M.L. Cirillo S., Sarnachiaro F., Faccioli G., Pivonello R., Cataldi M., Merola B., Annunziato L., Lombardi G. Long-term and low-dose treatment with cabergoline induces macroprolactinomas shrinkage. J. Clin. Endocrinol. Metab. 1997, 82: 3574.

    Article  CAS  PubMed  Google Scholar 

  24. Chiodini P., Liuzzi A., Cozzi R., Verde G., Opizzi G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G., Lucarelli G., Rainer E., Horowski R. Size reduction of macroprolactinomas by bromocrip-tine or lisuride treatment. J. Clin. Endocrinol. Metab. 1981, 53: 737.

    Article  CAS  PubMed  Google Scholar 

  25. Melis G.B., Gambacciani M., Paoletti A.M., Mais V., Sghedoni D., Fioretti P. Reduction in the size of prolactin-producing pituitary tumor after cabergoline administration. Fertil. Steril. 1989, 52: 412.

    CAS  PubMed  Google Scholar 

  26. Muratori M., Arosio M., Gambino G., Romano C., Biella O., Faglia G. Use of cabergoline in the long-term treatment of hy-perprolactinemic and acromegalic patients. J. Endocrinol. Invest. 1997, 20: 537.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Endocrinologia, Università di Messina, viale S. Martino 380, 98122, Messina, Italy

    S. Cannavò M.D., L. Curtò, S. Squadrito, B. Almoto, A. Vieni & F. Trimarchi

Authors
  1. S. Cannavò M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Curtò
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Squadrito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Almoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Vieni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Trimarchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Cannavò M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cannavò, S., Curtò, L., Squadrito, S. et al. Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22, 354–359 (1999). https://doi.org/10.1007/BF03343573

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343573

Key words

Search

Navigation